Mild To Moderate Plaque Psoriasis Market

• The Mild-to-Moderate Plaque Psoriasis Market Size is anticipated to increase with a notable CAGR during the forecast period (2023-2032).
• The leading Mild-to-moderate Plaque Psoriasis Companies such as AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, and others.
• Most Psoriasis Patients (78%) have mild or moderate illness ( 10% body surface area involved), with mild disease accounting for 50% of cases ( 3% body surface area involved). Only 2% of individuals have a body surface area involvement greater than 50%. 

Request for Unlocking the Sample Page of the "Mild-to-moderate Plaque Psoriasis Treatment Market"

DelveInsight’s “Mild-to-moderate Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Mild-to-moderate Plaque Psoriasis, historical and forecasted epidemiology as well as the Mild-to-moderate Plaque Psoriasis market trends in the United States, EU4 (Germany, France, Italy, Spain), and  the United Kingdom, and Japan.

The Mild-to-moderate Plaque Psoriasis Treatment Market Report provides current treatment practices, emerging drugs, Mild-to-moderate Plaque Psoriasis market share of the individual therapies, and current and forecasted Mild-to-moderate Plaque Psoriasis market size from 2019 to 2032, segmented by seven major markets. The report also covers current Mild-to-moderate Plaque Psoriasis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Mild-to-moderate Plaque Psoriasis Treatment Market: Understanding and Algorithm

The DelveInsight’s Mild-to-moderate Plaque Psoriasis market report gives a thorough understanding of Mild-to-moderate Plaque Psoriasis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Psoriasis is an immune-mediated chronic, skin disease that speeds up the growth cycle of skin cells (skin cells to multiply up to 10 times faster than normal). Psoriasis causes patches of thick red skin and silvery scales, and are extremely itchy in nature. Patches are typically found on the elbows, knees, scalp, lower back, face, palms, and soles of feet, but can affect other places (fingernails, toenails, and mouth). The most common type of psoriasis (~80% of all psoriasis cases) is called plaque psoriasis.

Mild-to-moderate Plaque Psoriasis Diagnosis

To diagnose psoriasis, skin, scalp, and nails for signs of the condition is examined. A biopsy is a test in which a pathologist examines skin cells under a microscope to determine whether psoriasis is the cause of symptoms. Dermatologists usually perform what's known as a punch biopsy.

Mild-to-moderate Plaque Psoriasis Treatment

According to treatment guidelines from the American Academy of Dermatology (AAD), therapeutic intervention for localized mild-to-moderate plaque psoriasis should begin with patient education and the use of topical corticosteroids with or without coal tar or calcipotriene. Thereafter, anthralin or tazarotene, alone or in combination with steroids, can be used following first-line treatment failure or subsequent loss of response to first-line therapy. Alternatively, if control is difficult to achieve or disease is widespread, phototherapy, with and without drugs such as psoralen or retinoids, may be required.

Mild-to-moderate Plaque Psoriasis Epidemiology

The Mild-to-moderate Plaque Psoriasis epidemiology section provides insights into historical and current Mild-to-moderate Plaque Psoriasis patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Mild-to-moderate Plaque Psoriasis report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings

• In an online cross-sectional survey by Gupta et al. (2021) in the US, of the 175 patients with mild-to-moderate plaque psoriasis who completed the survey, 67.4% were female, with a median age of 55.0 years and 10.8 years since plaque psoriasis diagnosis.
• The Mild-to-moderate Plaque Psoriasis epidemiology covered in the report provides historical as well as forecasted Mild-to-moderate Plaque Psoriasis epidemiology [segmented as Total Mild-to-Moderate Plaque Psoriasis Prevalent cases, Mild-to-Moderate Plaque Psoriasis Gender-Specific Prevalent cases, and Mild-to-Moderate Plaque Psoriasis Age-Specific Cases in the 7MM, covering the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Mild-to-moderate Plaque Psoriasis Epidemiology

The epidemiology segment also provides the Mild-to-moderate Plaque Psoriasis epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Mild-to-moderate Plaque Psoriasis Drugs Market Chapters

The drug chapter segment of the Mild-to-moderate Plaque Psoriasis Therapeutics Market Report encloses the detailed analysis of Mild-to-moderate Plaque Psoriasis marketed drugs and late-stage (Phase III and Phase II) Mild-to-moderate Plaque Psoriasis Pipeline Drugs. It also helps understand the Mild-to-moderate Plaque Psoriasis Clinical Trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Mild-to-moderate Plaque Psoriasis Marketed Drugs

• Otezla: Amgen

Otezla is the only pill approved to treat mild, moderate, and severe plaque psoriasis. Otezla works to reduce PDE4 activity. PDE4 is an enzyme that is believed to contribute to the inflammation associated with plaque psoriasis, though the exact way in which Otezla helps improve symptoms isn't completely understood.

Note: Detailed Current therapies assessment will be provided in the full report...

Emerging Mild-to-moderate Plaque Psoriasis Drugs

• SGX302: Soligenix 

SGX302 is a photodynamic light therapy for psoriasis treatment which uses synthetically manufactured hypericin applied as an ointment and activated with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light.

• AKP02/AKVANO: Lipidor AB

AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO technology. The aim with AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate plaque psoriasis.

Mild-to-moderate Plaque Psoriasis Market Outlook

Topical therapeutic agents are the first-line treatments for localized psoriasis. However, light therapy is also commonly used in mild to moderate plaque psoriasis. Common sources of light therapy used in the management of plaque psoriasis include whole-body or targeted ultraviolet (UV) B (broad and narrow band), photochemotherapy (psoralen with UVA (PUVA)), home phototherapy and LASER. Systemic drugs used include acitretin, methotrexate, cyclosporine, tacrolimus, hydroxyurea, 6-thioguanine, mycophenolate, fumaric acid esters, apremilast and biologic agents. Of the available biologic agents, etanercept, adalimumab, infliximab, secukinumab, ustekinumab, tildrakizumab and ixekizumab are indicated for plaque psoriasis.

According to DelveInsight, the Mild-to-moderate Plaque Psoriasis Treatment Market in 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Mild-to-moderate Plaque Psoriasis Treatment Market in 7MM.

The United States: Mild-to-Moderate Plaque Psoriasis Market Outlook

This section provides the total Mild-to-moderate Plaque Psoriasis Treatment Market Size and market size by therapies in the United States.

EU4 and the UK Countries: Mild-to-moderate Plaque Psoriasis Market Outlook

The total Mild-to-moderate Plaque Psoriasis Treatment Market Size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Mild-to-Moderate Plaque Psoriasis Market Outlook

The total Mild-to-moderate Plaque Psoriasis Treatment Market Size and market size by therapies in Japan are also mentioned.

Mild-to-moderate Plaque Psoriasis Drugs Uptake

This section focuses on the rate of uptake of the potential Mild-to-Moderate Plaque Psoriasis drugs recently launched in the Mild-to-moderate Plaque Psoriasis market or expected to get launched in the market during the study period 2019–2032. The analysis covers Mild-to-moderate Plaque Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug. This will help in understanding the Mild-to-moderate Plaque Psoriasis drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Mild-to-moderate Plaque Psoriasis Pipeline Development Activities

The Mild-to-moderate Plaque Psoriasis Therapeutics Market Report provides insights into Mild-to-moderate Plaque Psoriasis Clinical Trials within Phase II, and Phase III stages. It also analyses Mild-to-Moderate Plaque Psoriasis Companies involved in developing targeted therapeutics.

Development Activities

The Mild-to-Moderate Plaque Psoriasis Therapeutics Market Report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Mild-to-moderate Plaque Psoriasis emerging therapies.

Mild-to-moderate Plaque Psoriasis 

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Mild-to-moderate Plaque Psoriasis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Mild-to-moderate Plaque Psoriasis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and Mild-to-Moderate Plaque Psoriasis Drugs Market intelligence analysis of the Mild-to-moderate Plaque Psoriasis market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Mild-to-Moderate Plaque Psoriasis Therapeutics Market Report Scope

• Descriptive overview of Mild-to-moderate Plaque Psoriasis, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Mild-to-moderate Plaque Psoriasis epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and Mild-to-Moderate Plaque Psoriasis Emerging Therapies, along with the assessment of new therapies, expected to have an impact on the current Mild-to-Moderate Plaque Psoriasis Treatment Market Landscape
• Exhaustive analysis of the Mild-to-moderate Plaque Psoriasis Treatment Market; historical and forecasted, covering drug outreach in the 7MM
• Detailed patient-based Mild-to-Moderate Plaque Psoriasis market forecasting determines the trends shaping and driving the global Mild-to-moderate Plaque Psoriasis drugs market

Mild-to-moderate Plaque Psoriasis Therapeutics Market Report Highlights

• In the coming years, the Mild-to-moderate Plaque Psoriasis Market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug Mild-to-Moderate Plaque Psoriasis manufacturers to penetrate more into the market
• The Mild-to-Moderate Plaque Psoriasis Companies and academics are working to assess challenges and seek opportunities that could influence Mild-to-moderate Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major Mild-to-Moderate Plaque Psoriasis Companies are involved in developing Mild-to-Moderate Plaque Psoriasis Therapies. The launch of Mild-to-Moderate Plaque Psoriasis Emerging Therapies will significantly impact the Mild-to-moderate Plaque Psoriasis Drugs Market
• A better understanding of Mild-to-moderate Plaque Psoriasis pathogenesis will also contribute to the development of novel therapeutics for Mild-to-moderate Plaque Psoriasis.
• Our in-depth analysis of the Mild-to-moderate Plaque Psoriasis Pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Mild-to-Moderate Plaque Psoriasis Clinical Trials profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Mild-to-moderate Plaque Psoriasis Therapeutics Market Report Insights

• Mild-to-moderate Plaque Psoriasis Patient-Based Market Forecasting
• Mild-to-moderate Plaque Psoriasis Therapeutic Approaches
• Mild-to-moderate Plaque Psoriasis Pipeline Drugs Analysis
• Mild-to-moderate Plaque Psoriasis Market Size and trends
• Mild-to-moderate Plaque Psoriasis Drugs Market opportunities
• Impact of Upcoming Mild-to-moderate Plaque Psoriasis Therapies

Mild-to-moderate Plaque Psoriasis Therapeutics Market Report Key Strengths

• 10 year Mild-to-Moderate Plaque Psoriasis Market Forecast
• 7MM Coverage
• Mild-to-moderate Plaque Psoriasis epidemiology segmentation
• Key cross competition
• KOL views
• Mild-to-moderate Plaque Psoriasis Drug uptake

Mild-to-moderate Plaque Psoriasis Therapeutics Market Report Assessment

• Current Mild-to-moderate Plaque Psoriasis Treatment practices
• Mild-to-moderate Plaque Psoriasis Unmet Needs
• Mild-to-moderate Plaque Psoriasis Pipeline Drugs Profiles
• Mild-to-moderate Plaque Psoriasis market attractiveness

Key Questions Answered In The Report

Mild-to-moderate Plaque Psoriasis Market Insights:

• What would be the Mild-to-moderate Plaque Psoriasis Drugs Market Growth till 2032, and what will be the resultant market size in 2032?
•  What was the Mild-to-moderate Plaque Psoriasis Drugs Market Share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Mild-to-moderate Plaque Psoriasis Market Size and market size by therapies across the 7MM during the forecast period (2023–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Mild-to-moderate Plaque Psoriasis Market Size during the forecast period (2023–2032)?
• How would the unmet needs affect the Mild-to-moderate Plaque Psoriasis market dynamics and subsequent analysis of the associated trends?

Mild-to-moderate Plaque Psoriasis Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Mild-to-moderate Plaque Psoriasis?
• What is the historical and forecasted Mild-to-moderate Plaque Psoriasis patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain), and the UK, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Mild-to-moderate Plaque Psoriasis in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Mild-to-moderate Plaque Psoriasis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mild-to-moderate Plaque Psoriasis and its status, along with the challenges faced?

Reasons to Buy

• The patient-based Mild-to-Moderate Plaque Psoriasis Market Forecast analysis will help in developing business strategies by understanding trends shaping and driving the Mild-to-moderate Plaque Psoriasis Drugs Market
• Organize sales and marketing efforts by identifying the best opportunities for Mild-to-moderate Plaque Psoriasis in the US, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan
• Identification of strong upcoming Mild-to-Moderate Plaque Psoriasis Companies in the market that will help devise strategies that will help in getting ahead of competitors

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs